《生命科学》 2022, 34(8): 1046-1053

肝癌特异性分子标志物glypican-3的研究进展

韩乃寒^1,2,* , 武墨青¹ , 陈　跃¹ , 王文爽² , 李福川²

¹山东警察学院刑事科学技术系，济南 250200 ²山东大学国家糖工程技术研究中心，济南 250200

摘　要：

肝细胞癌(hepatocellular carcinoma, HCC) 是世界上最常见的癌症之一，死亡率极高，因而HCC 的早期诊断十分重要。磷脂酰肌醇蛋白-3 (glypican-3, GPC3) 的mRNA 和蛋白质表达水平在HCC 患者体内显著增高，但在正常人和良性肝病患者体内不表达或低水平表达，因此已成为HCC 诊断和靶向治疗的特异性生物标志物。本文对GPC3 的最新研究进展进行了详细综述，包括其分子结构、生物学功能、在HCC 发展过程中的作用、血清学检测方法以及以之为靶点的HCC 靶向治疗等。

通讯作者：韩乃寒 , Email:hannaihan@sdpc.edu.cn

Research progress of glypican-3, a specific molecular marker for liver cancer

HAN Nai-Han^1,2,* , WU Mo-Qing¹ , CHEN Yue¹ , WANG Wen-Shuang² , LI Fu-Chuan²

¹Department of Criminal Science and Technology, Shandong Police College, Jinan 250200, China ²National Glycoengineering Research Center, Shandong University, Jinan 250200, China

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common cancers with a very high mortality rate in the world, so early diagnosis of HCC is very important. Glypican-3 (GPC3) has significantly increased mRNA and protein expression levels in HCC patients, but is not expressed or expressed at low levels in normal person and patients with benign liver diseases. It has become a specific biomarker for the diagnosis and targeted therapy of HCC. In this paper, we review the latest research progress of GPC3 in detail, including its molecular structure, biological function, role in the development of HCC, serological detection methods as well as the targeted therapy of HCC against it.

Communication Author：HAN Nai-Han , Email:hannaihan@sdpc.edu.cn